|
|
|
|
| LEADER |
00000cam a2200000Mi 4500 |
| 001 |
EBOOKCENTRAL_on1048922805 |
| 003 |
OCoLC |
| 005 |
20240329122006.0 |
| 006 |
m o d |
| 007 |
cr |n|---||||| |
| 008 |
180818s2018 xx o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d YDX
|d OCLCQ
|d N$T
|d OCLCO
|d OCLCF
|d OCLCO
|d K6U
|d OCLCQ
|d OCLCO
|d OCLCL
|
| 019 |
|
|
|a 1048941591
|
| 020 |
|
|
|a 168108337X
|
| 020 |
|
|
|a 9781681083377
|q (electronic bk.)
|
| 029 |
1 |
|
|a AU@
|b 000070391920
|
| 035 |
|
|
|a (OCoLC)1048922805
|z (OCoLC)1048941591
|
| 050 |
|
4 |
|a RM371
|
| 082 |
0 |
4 |
|a 616.97061
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Frontiers in Clinical Drug Research.
|n Volume 3,
|p Anti-Allergy Agents.
|
| 260 |
|
|
|a Sharjah :
|b Bentham Science Publishers,
|c 2018.
|
| 300 |
|
|
|a 1 online resource (257 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Frontiers in Clinical Drug Research - Anti-Allergy Agents Ser. ;
|v v. 3
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Intro; CONTENTS; PREFACE; List of Contributors; Developing the Perfect Antihistamine for Use in Allergic Conditions: A Voyage in H1 Selectivity; Diana R. Cundell* and Kathryn E. Mickle; INTRODUCTION; Pharmacology of Histamine; Cellular Sources of Histamine and Mechanisms of Release; Mast Cells and the Inflammatory Environment; Histamine and Body Tissues; Antihistamines for the Treatment of Allergies; Nasal Anatomy and Physiology, Allergic Rhinitis, Allergens and Histamine; Allergens and Allergic Rhinitis; The Eye Conjunctiva; Anatomy And Physiology, Allergic Conjunctivitis and Histamine.
|
| 505 |
8 |
|
|a Allergens and Allergic ConjunctivitisThe Skin; Anatomy and Physiology, Urticaria and Histamine; Allergens and Urticaria; Histamine and the H1 Receptor; First Generation H1 Antihistamines; A History of First Generation Antihistamine Development; Ethylenediamines and Ethanolamines; Piperazines and Piperidines; Phenothiazines and Doxepin; A New Genre of Antihistamines With Powerful Central Nervous System Effects; Side Effects of The First Generation H1 Antihistamines and Toxicity; Central Nervous System H1 Side Effects.
|
| 505 |
8 |
|
|a Adverse Effects of First Generation H1 Antihistamines Due to Lack of SelectivityToxicity of First Generation Antihistamines; Second Generation H1 Antihistamines; Safer with Less Side Effects; Second Generation Antihistamines With Significant Side Effects: Astemizole, Azelastine and Terfenadine; Second Generation Histamines That are First Generation Analogs; Acrivastine, Cetirizine and Levocetirizine; Cetirizine; Levocetirizine; Second Generation Piperidine Successes; Levocabastine, Loratadine, Desloratadine, Fexofenadine, and Olopatadine; Loratadine; Desloratadine; Fexofenadine.
|
| 505 |
8 |
|
|a OlopatadineClinical Trial Meta-Analysis Data for Extensively Used Second Generation Antihistamines; CONCLUSION AND FURTHER DIRECTIONS; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Therapeutics in Chronic Spontaneous Urticaria; Alexei Gonzalez-Estrada* and James Fernandez; INTRODUCTION; TREATMENT; ANTIHISTAMINES; H1-Antihistamines; FIRST-GENERATION H1-ANTIHISTAMINES; Hydroxyzine; Doxepin; SECOND-GENERATION H1-ANTIHISTAMINES; Cetirizine; Desloratadine; Loratadine; Fexofenadine; Levocetirizine; Rupatadine; H2-Antihistamines; Cimetidine; Ranitidine; Famotidine.
|
| 505 |
8 |
|
|a Leukotriene AntagonistMontelukast; Zafirlukast; IMMUNOSUPPRESSIVE MEDICATIONS FOR CSU; Hydroxychloroquine; Colchicine; Dapsone; Sulfasalazine; Methotrexate; Cyclosporine; IMMUNOMODULATORY AGENTS; Omalizumab; Intravenous Immunoglobulin; Corticosteroids; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Research and Development for Anti-Asthmatic Agents with a Focus on Phenotype Changing by Ca2+ Signaling in Airway Smooth Muscle Cells; Hiroaki Kume1,2,*; INTRODUCTION; MECHANISM OF AIRWAY SMOOTH MUSCLE TONE; AIRWAY SMOOTH MUSCLE TONE REGULATED BY KCA CHANNELS.
|
| 500 |
|
|
|a Characteristics and physiological roles of KCa channels.
|
| 590 |
|
|
|a ProQuest Ebook Central
|b Ebook Central Academic Complete
|
| 650 |
|
0 |
|a Antiallergic agents.
|
| 650 |
|
0 |
|a Clinical medicine.
|
| 650 |
|
0 |
|a Medical innovations.
|
| 650 |
|
2 |
|a Anti-Allergic Agents
|
| 650 |
|
2 |
|a Clinical Medicine
|
| 650 |
|
6 |
|a Antiallergiques.
|
| 650 |
|
6 |
|a Médecine clinique.
|
| 650 |
|
6 |
|a Médecine
|x Innovations.
|
| 650 |
|
7 |
|a Antiallergic agents
|2 fast
|
| 650 |
|
7 |
|a Clinical medicine
|2 fast
|
| 650 |
|
7 |
|a Medical innovations
|2 fast
|
| 700 |
1 |
|
|a Rahman, Atta-ur-,
|d 1942-
|1 https://id.oclc.org/worldcat/entity/E39PBJx8yHRKtPYdRvxrTpJYyd
|
| 758 |
|
|
|i has work:
|a Frontiers in Clinical Drug Research Volume 3 Anti-Allergy Agents (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCGc6889kxGRHd6pJXphcrm
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|a Atta-ur-Rahman.
|t Frontiers in Clinical Drug Research - Anti-Allergy Agents: Volume 3.
|d Sharjah : Bentham Science Publishers, ©2018
|z 9781681083384
|
| 830 |
|
0 |
|a Frontiers in Clinical Drug Research - Anti-Allergy Agents Ser.
|
| 856 |
4 |
0 |
|u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=5491306
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL5491306
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 15641784
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 1867482
|
| 994 |
|
|
|a 92
|b IZTAP
|
